DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07340437

Completed

Clinical Study of 18F-Exendin-4 in Insulinoma

Clinical Study of an ¹⁸F-labeled GLP-1R Probe in Insulinoma

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

20

actual

Study population

Oncology

Key I/E criterion

—

Primary endpoint

•Correlation between clinical indicators and PET/CT results

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07340437
Org study IDSichuanPPH-Insulinoma

Timeline

Milestones

Study start2023-02-01actual
Primary completion2025-10-31actual
Study completion2025-12-31actual
Study first posted2026-01-14actual
Last update posted2026-01-15actual

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Oncology

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Patients with diagnosed or highly suspected insulinoma.

Inclusion criteria

•biochemically confirmed hyperinsulinemic hypoglycemia (plasma glucose < 3.0 mmol/L, insulin > 3 μIU/mL, C-peptide > 0.6 ng/mL)
•surgical or biopsy-confirmed insulinoma or non-insulinoma pancreatogenous hypoglycemia syndrome, with definitive clinical diagnosis at discharge and comprehensive evaluation for hypoglycemia etiology during hospitalization.

Exclusion criteria

•unknown etiology of hypoglycemia at last follow-up
•patients clinically diagnosed with insulinoma but without subsequent surgical intervention or biopsy

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Correlation between clinical indicators and PET/CT results

Time frame:2 years

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.